RELEASE DATE: June 1, 2020
EXPIRATION DATE: June 1, 2021
This activity is designed to meet the educational needs of physicians, nurses, advanced practice clinicians, and pharmacists who manage patients with multiple sclerosis (MS).
Asymptomatic or subclinical progression occurs in all stages of multiple sclerosis (MS) and should be part of treatment decisions, especially in early MS when damage prevention is critical. However, much of MS treatment is focused on relapse prevention. The role of subclinical disease progression in MS is becoming more evident, but many questions remain on how to measure and treat it. Newer biomarkers may help to monitor progression and measure treatment effects. In this enduring webinar, three subject matter experts will discuss critical yet complex questions in MS management:
- Distinguishing between progressive and relapsing MS in the early stages
- How can subclinical MS be measured?
- Bridging scientific advances on subclinical progression with “real world” practice
Edward J. Fox, MD, PhD, FAAN
Director, Multiple Sclerosis Clinic of Central Texas
Round Rock, TX
Clinical Assistant Professor of Neurology
University of Texas Medical Branch
Sarah A. Morrow, MD, MS, FRCPC, FAAN
Associate Professor of Neurology
Department of Clinical Neurological Sciences
University of Western Ontario
London, Ontario, Canada
Scott Newsome, DO, MSCS, FAAN
Associate Professor of Neurology
Director, Neurosciences Consultation and Infusion Center at Green Spring Station
Co-Director, Multiple Sclerosis Experimental Therapeutics Program
Division of Neuroimmunology and Neuroinfectious Diseases
Johns Hopkins Hospital
Delaware Media Group
PO Box 937, Glen Rock, NJ 07452-0937
Edward J. Fox has received consultant fees from Biogen, Celgene, EMD Serono, Genentech, Novartis, Teva, and TG Therapeutics; served on speaker’s bureaus for Biogen, EMD Serono, Genentech, Novartis, Teva; and has received research funding from AbbVie, Biogen, Celgene, Chugai, EMD Serono, Genentech, Novartis, Roche, Sanofi Genzyme, and TG Therapeutics.
Sarah A. Morrow has received consultant fees from Biogen, Celgene, EMD Serono, Novartis, Roche, Sanofi Genzyme, and Teva; has served on speakers bureaus for Biogen, EMD Serono, Roche, and Sanofi Genzyme; and has received research funding from AbbVie, Biogen, EMD Serono, Roche, and Sanofi Genzyme.
Scott Newsome has received consultant fees from Biogen, BioIncept, Celgene, EMD Serono, and Genentech; and has received research funding from Biogen and Genentech.
Laurie Scudder, DNP, NP has served as both a planner and reviewer for this activity and has disclosed no relevant financial relationships.
The following planners and managers have disclosed no relevant financial relationships: Joseph J. D’Onofrio, Frank Marino, Katherine Wandersee.
- Analyze clinical and diagnostic factors that guide the diagnosis of progressive multiple sclerosis (MS) across the spectrum of disease
- Discuss implications for treatment when a diagnosis of primary progressive MS is suspected
- Describe methods of assessment for subclinical or asymptomatic progression of MS including new biomarkers and investigative approaches
- Discuss the role of patient-centered outcomes in the assessment of clinical and subclinical progression in MS and appropriate strategies for patient education.
In support of improving patient care, this activity has been planned and implemented by the Consortium of Multiple Sclerosis Centers (CMSC) and Delaware Media Group. CMSC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The CMSC designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The CMSC designates this enduring material for 1.25 continuing education nursing credit (1.25 in the area of pharmacology).
The Consortium of Multiple Sclerosis Centers (CMSC) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education and will award 1.25 contact hours (.125 CEUs) to pharmacists who (1) participant in the activity, and (2) complete the evaluation form. The Universal Activity Number (UAN) for this activity isJA4008165-9999-20-024-H01-P. This is a knowledge-based activity.
The CMSC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria.
The CMSC designates this enduring material for 1.25 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
This webinar is supported by an educational grant from Genentech.
METHOD OF PARTICIPATION
Follow these steps to earn CE credit:
- Read the target audience, learning objectives, and author disclosures.
- Study the educational content online or during the enduring webinar program.
- Complete the post test and evaluation at the end of the activity.
There is no fee to participate in this educational activity.
If you have any questions about this CE activity, please contact the CMSC at firstname.lastname@example.org or 201-487-1050.
DISCLOSURE OF UNLABELED USE
This CE activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA. CMSC, Delaware Media Group, and the supporters do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of CMSC, Delaware Media Group, or the supporters.
Copyright © 2020, Delaware Media Group, Inc. All rights reserved. None of the contents of this webinar program may be reproduced in any form without prior written permission. The opinions expressed in this program are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, or the supporters.